The Association of Cancer Care Centers and LUNGevity have launched the Electronic Health Records Integrations for Biomarker Testing: Roadmap, a new virtual resource to support multidisciplinary cancer care teams prepare, implement, and evaluate electronic health record integrations for biomarker testing.
Tagrisso (osimertinib) plus chemotherapy delivers a statistically significant and clinically meaningful survival benefit compared to Tagrisso monotherapy in the first-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer, according to results from the final overall survival analysis of the FLAURA2 phase III trial.
